Interest in peptides has grown sharply: GHK-Cu search volume alone rose more than 1,000% year over year between 2025 and 2026, and the broader peptide therapeutics market reached roughly $48 billion in 2025
When combined with semaglutide in CagriSema, the glycemic improvements were substantial
The key difference is that retatrutide provides triple agonism (GLP-1 + GIP + glucagon) while semaglutide provides only GLP-1 agonism
While all three vendors offer popular muscle-focused peptides, LeoLab RX differentiates itself through a stronger emphasis on transparency and completeness
They are not approved for human or veterinary use , and are not intended to diagnose, treat, cure, or prevent any disease
Phase 2b completed in T2D) Status: Investigational not approved by FDA or EMA Heres what makes it different from everything else on the market and in the pipeline: - Semaglutide (Ozempic/Wegovy/Rybelsus): GLP-1 only - Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP - Retatrutide (investigational): GLP-1 + GIP + Glucagon - Amycretin : GLP-1 + Amylin Different receptor pairing
